JP2014509515A - エリブリンに対する応答を予測するための方法及び組成物 - Google Patents

エリブリンに対する応答を予測するための方法及び組成物 Download PDF

Info

Publication number
JP2014509515A
JP2014509515A JP2013558214A JP2013558214A JP2014509515A JP 2014509515 A JP2014509515 A JP 2014509515A JP 2013558214 A JP2013558214 A JP 2013558214A JP 2013558214 A JP2013558214 A JP 2013558214A JP 2014509515 A JP2014509515 A JP 2014509515A
Authority
JP
Japan
Prior art keywords
biomarker
eribulin
subject
expression level
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013558214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014509515A5 (enExample
Inventor
アゴウルニク，セルゲイ・アイ
バーン，マイケル・チヤツプマン
リトルフイールド，ブルース・エイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2014509515A publication Critical patent/JP2014509515A/ja
Publication of JP2014509515A5 publication Critical patent/JP2014509515A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
JP2013558214A 2011-03-18 2012-03-16 エリブリンに対する応答を予測するための方法及び組成物 Pending JP2014509515A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161454426P 2011-03-18 2011-03-18
US61/454,426 2011-03-18
PCT/US2012/029479 WO2012129100A1 (en) 2011-03-18 2012-03-16 Methods and compositions for predicting response to eribulin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017046070A Division JP6612280B2 (ja) 2011-03-18 2017-03-10 エリブリンに対する応答を予測するための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2014509515A true JP2014509515A (ja) 2014-04-21
JP2014509515A5 JP2014509515A5 (enExample) 2015-04-23

Family

ID=45879070

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013558214A Pending JP2014509515A (ja) 2011-03-18 2012-03-16 エリブリンに対する応答を予測するための方法及び組成物
JP2017046070A Expired - Fee Related JP6612280B2 (ja) 2011-03-18 2017-03-10 エリブリンに対する応答を予測するための方法及び組成物
JP2019069638A Pending JP2019150027A (ja) 2011-03-18 2019-04-01 エリブリンに対する応答を予測するための方法及び組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017046070A Expired - Fee Related JP6612280B2 (ja) 2011-03-18 2017-03-10 エリブリンに対する応答を予測するための方法及び組成物
JP2019069638A Pending JP2019150027A (ja) 2011-03-18 2019-04-01 エリブリンに対する応答を予測するための方法及び組成物

Country Status (8)

Country Link
US (1) US9637795B2 (enExample)
EP (1) EP2686441B1 (enExample)
JP (3) JP2014509515A (enExample)
CN (1) CN103562406B (enExample)
CA (1) CA2828959A1 (enExample)
ES (1) ES2731653T3 (enExample)
SG (2) SG10201602147YA (enExample)
WO (1) WO2012129100A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016501213A (ja) * 2012-12-04 2016-01-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がんの処置におけるエリブリンの使用
WO2016178374A1 (ja) * 2015-05-01 2016-11-10 国立研究開発法人科学技術振興機構 腫瘍細胞の悪性化抑制剤及び抗腫瘍剤
WO2020179712A1 (en) * 2019-03-01 2020-09-10 Eisai R&D Management Co., Ltd. Methods for predicting tumor response to eribulin

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120923A1 (es) 2009-03-30 2012-08-27 Eisai Randd Man Co Ltd Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismo
CN105338977B (zh) * 2013-06-26 2018-10-16 卫材R&D管理有限公司 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
JP6648040B2 (ja) * 2014-05-28 2020-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用
WO2015183961A1 (en) * 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd Use of eribulin in the treatment of cancer
MX386547B (es) 2015-03-04 2025-03-19 Merck Sharp & Dohme Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer.
MY199595A (en) 2016-03-02 2023-11-08 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
WO2017188350A1 (ja) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
EP3713565A1 (en) 2017-11-20 2020-09-30 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
ES3075649T3 (en) 2019-07-26 2026-08-06 Eisai R&D Man Co Ltd Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CN113174427B (zh) * 2021-04-29 2023-02-28 遵义医科大学 基于DNA分子检测ERGIC3 mRNA的方法
CN113512733B (zh) * 2021-05-13 2022-07-26 浙江工业大学 一种电化学nhk反应合成艾日布林中间体的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032347A2 (en) * 2003-10-01 2005-04-14 The Ohio State University Research Foundation Determining the chemosensitivity of cells to cytotoxic agents
JP2008522623A (ja) * 2004-12-09 2008-07-03 エーザイ株式会社 ハリコンドリンｂアナログを使用した癌治療でのチューブリンアイソタイプのスクリーニング

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5075216A (en) 1988-09-23 1991-12-24 Cetus Corporation Methods for dna sequencing with thermus aquaticus dna polymerase
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
DE69233087T2 (de) 1991-11-22 2003-12-24 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verfahren zur Herstellung von Polymerarrays
ATE267877T1 (de) 1993-01-07 2004-06-15 Sequenom Inc Dns - sequenzierung durch massenspektronomie
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
JP2001521753A (ja) 1997-10-31 2001-11-13 アフィメトリックス インコーポレイテッド 成人臓器及び胎児臓器中の発現プロフィール
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
CA2632433C (en) 1998-06-17 2012-02-07 Eisai R & D Management Co., Ltd. Methods for preparing macrocyclic analogs and intermediates for preparing same
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
WO2011109637A1 (en) * 2010-03-03 2011-09-09 Koo Foundation Sun Yat-Sen Cancer Center Methods for classifying and treating breast cancers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032347A2 (en) * 2003-10-01 2005-04-14 The Ohio State University Research Foundation Determining the chemosensitivity of cells to cytotoxic agents
JP2008522623A (ja) * 2004-12-09 2008-07-03 エーザイ株式会社 ハリコンドリンｂアナログを使用した癌治療でのチューブリンアイソタイプのスクリーニング

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6016004230; Ｔｈｅ　Ｌａｎｃｅｔ Ｖｏｌ．３７７, 20110312, ｐ．９１４-９２３ *
JPN6016004232; Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．６１, 2001, ｐ．１０１３-１０２１ *
JPN6016004234; Ｊｏｕｒｎａｌ　ｏｆ　Ｃｌｉｎｉｃａｌ　Ｏｎｃｏｌｏｇｙ Ｖｏｌ．２８，　Ｎｏ．２５, 2010, ｐ．３９２２-３９２８ *
JPN6016004236; Ｎａｔｕｒｅ Ｖｏｌ．４４６, 2007, ｐ．８１５-８１９ *
JPN6016004238; Ｇａｓｔｒｏｅｎｔｅｒｏｌｏｇｙ Ｖｏｌ．１３８, 2010, ｐ．９４９-９５７ *
JPN6016004240; Ｅｘｐｅｒｔ　Ｏｐｉｎｉｏｎ　ｏｎ　Ｐｈａｒｍａｃｏｔｈｅｒａｐｙ Ｖｏｌ．１１，　Ｎｏ．９, 2010, ｐ．１５８７-１５９３ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016501213A (ja) * 2012-12-04 2016-01-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がんの処置におけるエリブリンの使用
WO2016178374A1 (ja) * 2015-05-01 2016-11-10 国立研究開発法人科学技術振興機構 腫瘍細胞の悪性化抑制剤及び抗腫瘍剤
US10669545B2 (en) 2015-05-01 2020-06-02 Japan Science And Technology Agency Tumor cell malignant transformation suppressor and anti-tumor agent
WO2020179712A1 (en) * 2019-03-01 2020-09-10 Eisai R&D Management Co., Ltd. Methods for predicting tumor response to eribulin

Also Published As

Publication number Publication date
SG193489A1 (en) 2013-10-30
JP6612280B2 (ja) 2019-11-27
US20140235707A1 (en) 2014-08-21
SG10201602147YA (en) 2016-05-30
WO2012129100A1 (en) 2012-09-27
EP2686441B1 (en) 2019-05-08
JP2019150027A (ja) 2019-09-12
CN103562406B (zh) 2018-03-27
EP2686441A1 (en) 2014-01-22
US9637795B2 (en) 2017-05-02
CA2828959A1 (en) 2012-09-27
CN103562406A (zh) 2014-02-05
ES2731653T3 (es) 2019-11-18
JP2017148049A (ja) 2017-08-31

Similar Documents

Publication Publication Date Title
JP6612280B2 (ja) エリブリンに対する応答を予測するための方法及び組成物
EP3458604B1 (en) Method for determining sensitivity to a cdk4/6 inhibitor
CN103261413B (zh) 三剂并用抗癌剂感受性判定标记
Chen et al. The predictive role of E2-EPF ubiquitin carrier protein in esophageal squamous cell carcinoma
JPWO2016148115A1 (ja) ホスファチジルセリンシンターゼ１阻害剤への応答性を予測する方法
EP2722400A2 (en) Methods of using biomarkers
CN114381528B (zh) Mettl7a基因及其表达产物在诊断和治疗肿瘤中的用途
JP7167263B2 (ja) Ｐｍｖｋを有効成分として含む放射線抵抗性癌診断用または放射線治療予後予測用バイオマーカー組成物
KR102238258B1 (ko) 간암 진단을 위한 신규 바이오마커 및 이를 이용한 치료 방법
KR20110107768A (ko) 간암 진단 마커 및 치료제로서의 ｎｌｋ
US20230265526A1 (en) Cd133 related to anticancer agent resistance in colon cancer and use thereof
CN112462072B (zh) 一种tmub1蛋白在制备肿瘤免疫抑制分子检测剂中的应用
KR20240088113A (ko) 긴 비번역 rna linc01446을 이용한 간암 진단 또는 치료 용도
US20240102105A1 (en) Biomarker for predicting responsiveness to anticancer agent and use thereof
CN111910005A (zh) Cdk4/6抑制剂敏感性相关基因及其应用
US20260015672A1 (en) Biomarkers in pancreatic cancer
KR101370108B1 (ko) 위암 진단용 마커로서 ｈｄａｃ2의 용도
JP2014082953A (ja) 癌の検出方法、癌検出キット、癌治療薬のスクリーニング方法、及び癌治療薬
WO2023070121A1 (en) Compositions and methods for treatment of mic60 depleted cancers and metastasis
CN119367546A (zh) 用于增强胶质瘤化疗药物敏感性的组合物及其应用
CN121852536A (zh) m5C甲基转移酶NSUN2在制备多发性骨髓瘤诊治产品中的应用
JP2010200625A (ja) 食道がんに対する放射線化学療法感受性マーカー
KR20110096294A (ko) 간암 진단용 마커로서의 ｓ100ｐ의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160609

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170313